Lipoprotein (a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment

S Lampsas, M Xenou, E Oikonomou, P Pantelidis… - Molecules, 2023 - mdpi.com
Lipoprotein (a)(Lp (a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to
apolipoprotein (a). Increased Lp (a) levels are an independent, heritable causal risk factor …

Assessment of cardiovascular disease risk: a 2022 update

E Goldsborough, N Osuji… - … and Metabolism Clinics, 2022 - endo.theclinics.com
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with
atherosclerotic cardiovascular disease (ASCVD) being the dominant cause of total CVD …

Use of Lipoprotein (a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

DP Wilson, TA Jacobson, PH Jones… - Journal of clinical …, 2019 - Elsevier
Abstract Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …

A test in context: lipoprotein (a) diagnosis, prognosis, controversies, and emerging therapies

S Tsimikas - Journal of the American College of Cardiology, 2017 - jacc.org
Evidence that elevated lipoprotein (a)(Lp [a]) levels contribute to cardiovascular disease
(CVD) and calcific aortic valve stenosis (CAVS) is substantial. Development of isoform …

Effects of aerobic exercise on lipids and lipoproteins

Y Wang, D Xu - Lipids in health and disease, 2017 - Springer
Dyslipidemia is the risk of cardiovascular disease, and their relationship is clear. Lowering
serum cholesterol can reduce the risk of coronary heart disease. At present, the main …

NHLBI working group recommendations to reduce lipoprotein (a)-mediated risk of cardiovascular disease and aortic stenosis

S Tsimikas, S Fazio, KC Ferdinand… - Journal of the American …, 2018 - jacc.org
Pathophysiological, epidemiological, and genetic studies provide strong evidence that
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …

Lipoprotein (a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study

CM Madsen, PR Kamstrup, A Langsted… - … , and vascular biology, 2020 - ahajournals.org
Objective: High Lp (a)(lipoprotein [a]) cause cardiovascular disease (CVD) in a primary
prevention setting; however, it is debated whether high Lp (a) lead to recurrent CVD events …

Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or …

LR Saslow, JJ Daubenmier, JT Moskowitz, S Kim… - Nutrition & …, 2017 - nature.com
Dietary treatment is important in management of type 2 diabetes or prediabetes, but
uncertainty exists about the optimal diet. We randomized adults (n= 34) with glycated …

Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association

HE Bays, PP Toth, PM Kris-Etherton, N Abate… - Journal of clinical …, 2013 - Elsevier
The term “fat” may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes
and adipose tissue).“Lipid” is derived from “lipos,” which refers to animal fat or vegetable oil …

Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus …

MR Langlois, MJ Chapman, C Cobbaert… - Clinical …, 2018 - academic.oup.com
Abstract BACKGROUND The European Atherosclerosis Society–European Federation of
Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide …